Navigation Links
ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Date:12/16/2009

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated with the inflammation underlying certain autoimmune diseases, including RA. By selectively blocking the CCR1 receptor, CCX354 is designed to reduce the infiltration of inflammatory cells into the joints of RA patients and inhibiting the subsequent joint destruction while minimizing the potential for off-target effects, thus providing a wider therapeutic window than currently approved therapies. The high potency and selectivity of the molecule are expected to provide continuous receptor coverage throughout the dosing period which is thought to be critical for efficacy. Successful completion of single and multiple ascending dose Phase 1 studies in healthy volunteers showed that CCX354 was safe and well-tolerated.

"Initiation of a Phase 2 clinical development program for CCX354 marks yet another important milestone for ChemoCentryx and represents a unique opportunity to thoroughly evaluate a new mechanism of action for the potential treatment of rheumatoid arthritis," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We believe our CCR1 antagonist is best-in-class, surpassing the properties of previous molecules in this space, particularly in its ability to continuously cover the disease target, the CCR1 receptor. This study builds on our recent clinical success of demonstrating efficacy for Traficet-EN(TM), a novel drug which targets another chemokine receptor, in patients suffering from Crohn's disease. We
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
2. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
6. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
7. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
8. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
9. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
10. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... LONDON , May 22, 2015 ... early phase clinical research unit with a worldwide ... respected for its frequent publications in peer reviewed ... and European stakeholders and regulators in discussions about ... results.      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , ...
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3
... plc (Nasdaq: JAZZ ) today announced several ... company,s leadership team. The appointments include: ... company and will serve as general counsel and an ... in March.  Ms. Hooper is currently a partner at ...
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... a letter dated January 18, 2012 from The Nasdaq Stock ... from the Company,s Board of Directors effective January 4, 2012, ... Nasdaq,s requirement that its audit committee consists of at least ...
Cached Medicine Technology:Jazz Pharmaceuticals plc Announces New Executive Appointments 2Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement 2
(Date:5/25/2015)... 24Hr HomeCare is proud to announce that ... COO, and Ryan Iwamoto, Co-Founder & CMO, are Finalists ... 2015 Awards in Greater Los Angeles. The award is ... innovation, financial performance, and a personal commitment to their ... the ongoing success of our organization,” said Co-Founder & ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 Thousands ... to move forward in the federal multidistrict litigation ... of Texas. According to a Motion filed on ... to modify the Case Management Order pertaining to ... other things, the Motion seeks the adoption of ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 Tunstall Americas ... deliver the highest level of service to its Medical ... upgrades and a restructuring of resources, Tunstall now provides ... and the Medical Answering Service to ensure superior patient ... that it has invested over $10 million in expanded ...
(Date:5/24/2015)... The Rolling Stones Zip Code summer stadium ... Petco Park. This iconic group is ready for their ... had a warmup show in Los Angeles at the Henry ... this beloved band not only played their Sticky Fingers album ... "Jumping Jack Flash," "Moonlight Mile" and "All Down the ...
(Date:5/24/2015)... 24, 2015 Scientists with Cardno ChemRisk, ... air quality compliance issues that may have raised the ... Mesothelioma has just posted an article on the research. ... The group found airborne asbestos levels well above OSHA ... 1984 and 2011. , “Asbestos compliance sampling data associated ...
Breaking Medicine News(10 mins):Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2
... medical center implemented strict protocols for administering gadolinium-based ... cases for nephrogenic system fibrosis (NSF). Implementing ... diminished kidney function says Dr. Ozden Narin, presenting ... had some patients who developed NSF after they ...
... 1. For Older COPD Patients, Long-acting Inhaled Beta-agonists ... such as inhaled beta-agonists and anticholinergic agents are ... (COPD). Both drugs have been shown to decrease ... function, quality of life, and possibly mortality. However, ...
... Exposure to secondhand smoke, such as a person can get ... has a direct, measurable impact on the brainand the effect ... person doing the smoking. In fact, exposure to this secondhand ... by the National Institute on Drug Abuse (NIDA), part of ...
... American workers forced to travel often on business aren,t doing their ... of U.S. researchers found that people who travel for business 20 ... disease than "light" travelers who were on the go only a ... School of Public Health analyzed the medical records of more than ...
... (BRONX, NY) In honor of his significant clinical ... the World Trade Center following the September 11, 2001 ... 2011 Public Service Award from the American Thoracic Society ... at Albert Einstein College of Medicine of Yeshiva ...
... CO Doctors have long sought a way to directly ... skull. Now researchers have developed a way to get the ... poker-chip that rests on a patient,s head, according to findings ... Academic Societies in Denver. "This is the first time ...
Cached Medicine News:Health News:Embargoed news from Annals of Internal Medicine 2Health News:Embargoed news from Annals of Internal Medicine 3Health News:Frequent Business Travel Tough on the Heart, Study Finds 2Health News:Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers 2Health News:Researchers develop device to measure brain temperature non-invasively 2
Full Digital Ultrasound System...
Premium Full Color Digital Ultrasound...
... cardiovascular ultrasound system provides dedicated and ... all-digital ultrasound system offering exceptional image ... and spatial resolution everything you ... cardiovascular products. Designed specifically for ...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
Medicine Products: